Since the discovery of myostatin (MSTN; also known as GDF-8) as a critical regulator of
skeletal muscle mass in 1997, there has been an extensive effort directed at understanding …

Sarcopenia is a loss of muscle protein mass and loss of muscle function. It occurs with
increasing age, being a major component in the development of frailty. Current knowledge …

Current genome-editing systems generally rely on inducing DNA double-strand breaks
(DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by …

Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not
yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected …

The term uraemic myopathy has been used loosely to describe the skeletal muscle
abnormalities in uraemic patients. However, it does not fully explain the observed …

Current molecular genomic approaches to human genetic disorders have led to an
explosion in the identification of the genes and their encoded proteins responsible for these …

Becker muscular dystrophy (BMD) is a variant of dystrophin deficiency resulting from DMD
gene mutations. Phenotype is variable with loss of ambulation in late teenage or late mid-life …

Myostatin (GDF-8) was discovered 25 years ago as a new transforming growth factor-β
family member that acts as a master regulator of skeletal muscle mass. Myostatin is made by …

The skeletal muscle is the largest organ in the body, by mass. It is also the regulator of
glucose homeostasis, responsible for 80% of postprandial glucose uptake from the …

Myostatin is a TGF-β family member that normally acts to limit skeletal muscle mass.
Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and …